Avadel Pharmaceuticals (AVDL)
(Delayed Data from NSDQ)
$16.12 USD
-0.69 (-4.10%)
Updated May 14, 2024 04:00 PM ET
After-Market: $16.11 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
AVDL 16.12 -0.69(-4.10%)
Will AVDL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AVDL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AVDL
Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know
Here's Why You Should Invest in Avadel (AVDL) Stock Now
AVDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avadel (AVDL) is a Great Momentum Stock: Should You Buy?
How Much Upside is Left in Avadel (AVDL)? Wall Street Analysts Think 37.36%
Why Avadel Pharmaceuticals (AVDL) Stock Might be a Great Pick
Other News for AVDL
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Akero Therapeutics (AKRO) and Madrigal Pharmaceuticals (MDGL)
Avadel gains for a second day as analysts see it prevailing in case vs Jazz/FDA
Buy Rating Affirmed for Avadel Pharmaceuticals Amidst Strong Growth Potential and Market Expansion
Avadel Pharma gains during hearing over dispute on FDA approval of a sleep disorder drug (update)
Avadel Pharma gains during hearing over dispute on FDA approval of a sleep disorder drug